Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA ®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna’s circular RNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation ...

Jan 15, 2025 · Under the agreement, Simnova will pursue the research and development and commercialization of in vivo panCar cell therapies targeting BCMA in greater China and Orna will retain all rights for...

Orna’s proprietary circular RNA (oRNA) is engineered as linear RNA that self-circularizes. oRNA exhibits numerous advantages over traditional linear mRNA therapies such as simplified production, increased protein expression, and a superior immunogenicity profile.

Jan 7, 2025 · Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX...

Jan 7, 2025 · Orna's circular RNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression.

Jan 8, 2025 · Vertex Pharmaceuticals and Orna Therapeutics have announced a three-year collaboration to develop next-generation gene therapies for sickle cell disease (SCD) and transfusion-dependent beta ...

Jan 7, 2025 · Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna’s novel...

Jan 8, 2025 · Vertex Pharmaceuticals and Orna Therapeutics announce a $4 billion collaboration to develop in vivo gene editing therapies for sickle cell disease and beta-thalassemia. The partnership leverages Orna’s lipid nanoparticle delivery platform to advance next-generation hematopoietic stem cell therapies.

1月7日，Orna Therapeutics宣布与Vertex Pharmaceuticals进行为期三年的战略研究合作，利用Orna的新型专有LNP递送技术，助力Vertex为镰状细胞贫血症（SCD）和输血依赖性β地中海贫血（TDT）患者开发下一代基因编辑疗法。 根据协议，Orna将获得6500万美元的首付款，Orna还有资格根据在临床前、研究、开发、监管和商业等方面达到特定里程碑的情况，获得最高可达6.35亿美元的款项。 此外，如果Vertex选择额外适应症的权利，对于多达十种额外产品，Orna还有 …

Cambridge, Mass., February 24, 2021 – Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNAs), today announced the completion of its $80 million Series A financing.